{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-009487","form_type":"8-K","ticker":"SCYX","cik":"0001178253","company_name":"SCYNEXIS INC","filed_at":"2022-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.594546+00:00","generated_at":"2026-06-26T23:50:23.312305+00:00","sec_items":["2.03"],"event_type":"debt","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"SCYNEXIS receives $5M third tranche from Hercules/SVB Term Loan after CANDLE milestone","bullets":["On March 9, 2022, SCYNEXIS drew $5M under its existing $60M Term Loan with Hercules/SVB.","The tranche was triggered by positive Phase 3 CANDLE study results for ibrexafungerp.","Prior draws: $20M at closing (May 2021), $10M on FDA approval (June 2021).","Total drawn now $35M; remaining tranches subject to conditions.","Loan facility provided by Hercules Capital and Silicon Valley Bank."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-009487","json":"https://secwatch.observer/filing/0001564590-22-009487.json","markdown":"https://secwatch.observer/filing/0001564590-22-009487.md","text":"https://secwatch.observer/filing/0001564590-22-009487.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178253/000156459022009487/0001564590-22-009487-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178253/000156459022009487/scyx-8k_20220309.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T23:50:23.312305+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}